Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ATG 018

Next Previous
Drug Profile

ATG 018

Alternative Names: ATG-018

Latest Information Update: 02 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Antengene Corporation
  • Class Antineoplastics; Small molecules
  • Mechanism of Action ATR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Haematological malignancies; Solid tumours

Most Recent Events

  • 18 Jul 2024 Antengene Corporation terminates the phase I ATRIUM trial in Solid tumours and Haematological malignancies (Monotherapy, Late-stage disease, Second-line therapy or greater) in Australia (PO), due to lack of efficacy of study compound (NCT05338346)
  • 25 Aug 2023 Efficacy data from the phase I ATRIUM in Solid tumors and Haematologic malignancies released by Antengene Corporation
  • 14 Jun 2022 Phase-I clinical trials in Haematological malignancies (Monotherapy, Late-stage disease, Second-line therapy or greater) in Australia (PO) before June 2022 (NCT05338346) (Antengene Corporation pipeline, June 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top